FDA Investigator

Zhihao Pete Qiu

Latest inspection on record: Singapore, Singapore, September 2021 · records back to 2009

Human Drugs

FDA inspection record · Last updated July 12, 2026

Overview

  • 30 inspections across 30 sites are on record.
  • 25 Form 483 observations are attributed to this investigator.
  • Most recent recorded activity is 2021-09-03.

At a glance

Inspections

30

Sites

30

Observations

25

Career since

Jun 2009

Recent inspections

Most recent inspections in the published record.

SiteDateCategoryForm 483
MSD International GmbH (Singapore Branch)3 Sep 2021Human DrugsOn file
FujiFilm Diosynth Biotechnologies U.S.A., Inc.21 Apr 2021Human DrugsOn file
Chugai Pharma Manufacturing Co., Ltd21 Feb 2020Human DrugsOn file
GP PHARM S.A.U.21 May 2019Human DrugsView 483 →
Immunex Rhode Island Corporation19 Apr 2019Human DrugsOn file

Sites inspected

FujiFilm Diosynth Biotechnologies U.S.A., Inc.Research Triangle Park, United States1 insp.
Chugai Pharma Manufacturing Co., LtdUtsunomiya, Japan1 insp.
GP PHARM S.A.U.Sant Quinti De Mediona, Spain1 insp.
Immunex Rhode Island CorporationWest Greenwich, United States1 insp.

Co-investigators

Investigators who share inspections with this person.

Zhong Li2 shared
Laura Fontan2 shared
Yun Wu1 shared

Full investigator report

Get the verbatim findings behind Zhihao Pete Qiu's 25 observations

Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.

  • New inspections and Form 483s, mapped to the CFR citation
  • Warning letter outcomes, and the citation patterns they repeat
  • Their co-investigators, so no surprises about who shows up on site